

Prevalence of Asthma Severities in Children and Adolescents in a Wilmington, DE Hospital

Kevin McKinski, MPHc

Thomas Jefferson University

BACKGROUND

- Asthma affects over 24 million individuals in the US
- Prevalence of the condition is increasing in the US and worldwide
- Classified into 4 severities:
 - Intermittent
 - Mild Persistent
 - Moderate Persistent
 - Severe Persistent
- Children with severe persistent asthma experience symptoms every day, are extremely limited, and account for a sizeable portion of healthcare costs
- The prevalence of severe asthma in children and adolescents is poorly understood
- We aimed to define the prevalence of asthma severities in an urban inpatient setting across different demographics



METHODS

- Since most patients are already on long-term asthma medication, prescribed medications were used as a proxy for asthma severity according to NIH guidelines for care
- Study Population: All patients ages 5-18 with asthma that were admitted to pulmonology or allergy departments at Nemours Children's Hospital in Wilmington, DE between 01Nov2014 01Nov2017 and were prescribed at least one asthma medication



Prescribed Medications

Step of Treatment

Asthma Severity

RESULTS

Asthma Severities of the Study Population

	Ages 5-11		Ages 12-18	
	n	Freq. %	n	Freq. %
Asthma Severity				
Intermittent	70	10.97%	94	18.29%
Mild Persistent	121	18.97%	100	19.46%
Moderate Persistent	211	33.07%	135	26.26%
Severe Persistent	236	36.99%	185	35.99%

DISCUSSION

- We found that most children and adolescents who are hospitalized for asthma are moderate/severe asthmatics
- Those ages 5-11 are more likely to be hospitalized for moderate/severe asthma compared to those ages 12-18
- African Americans are more likely to be hospitalized for moderate/severe asthma compared to Whites
- This information can be used to generate hypotheses for future studies can be used to better address patient needs
- Future research to reduce prevalence might focus on:
 - Identification of more indicative risk factors
 - Earlier screening methods
 - New and more personalized therapies

Results of Chi-Square Tests

	Age Group	X ²	p
Age Groups	N/A	15.208	0.002
Sex	5-11	6.276	0.099
	12-18	1.715	0.634
Race	5-11	19.743	0.003
	12-18	18.244	0.006
Ethnicity	5-11	1.279	0.734
	12-18	1.040	0.792

Limitations

- Only generalizable to clinical inpatient settings with similar demographic patient base
- Prescribing habits of clinicians may not reflect what is actually recommended (Flovent 110 mg/act caused many ages 5-11 to be high-dose ICS but not 12-18)
- Those who did not fall into defined step of treatment were assumed to be moderate persistent asthmatics

Results of Binary Logistic Regression for moderate/severe compared to intermittent/mild

		X ²	p	AOR	95% CI
Age Gr	oup				
Ag	es 5-11	7.144	0.008	1.406	1.131 - 1.879
Ag	es 12-18 (Ref)				
Sex					
Ma	le	1.328	0.249	0.863	0.671 - 1.109
Fe	male (Ref)				
Race					
Af	rican American	14.893	<0.001	1.727	1.309 - 2.280
Ot	her	1.162	0.281	1.279	0.818 - 2.000
Wł	nite (Ref)				
Ethnici	ty				
No	n-Hisp. or Latino	0.313	0.576	0.886	0.579 - 1.355
His	sp. or Latino (Ref)				

ACKNOWLEDGEMENTS

- Dr. Katherine King (Nemours) for helping to refine my research focus and for offering the scientific guidance I needed to complete the project
- Dr. John McAna (Jefferson) for assisting with data analysis
- Dr. Kenneth Rogers (Nemours) for helping me to submit IRB proposal and helping me to obtain the Nemours dataset used in this study